M83.5 Other drug-induced osteomalacia in adults

Name of the Condition

• Other drug-induced osteomalacia in adults

Summary

Other drug-induced osteomalacia in adults is a metabolic bone disorder caused by medications that impair bone mineralization, leading to softened bones and increased fracture risk. It results from disrupted vitamin D metabolism or calcium/phosphate homeostasis due to drug effects.

Causes

This condition is caused by medications that interfere with vitamin D activation, calcium absorption, or phosphate metabolism. Common culprits include long-term use of anticonvulsants (e.g., phenytoin, phenobarbital), certain chemotherapy agents, or drugs that induce hepatic enzymes affecting vitamin D metabolism. These medications disrupt the normal process of bone mineralization.

Risk Factors

• Prolonged use of medications known to affect bone metabolism (e.g., anticonvulsants, certain chemotherapeutics).
• Pre-existing vitamin D or calcium deficiency.
• Chronic kidney disease or renal tubular disorders.
• Malabsorption conditions (e.g., celiac disease, Crohn’s disease).
• Advanced age or sedentary lifestyle.

Symptoms

• Diffuse bone pain, particularly in the hips, lower back, or legs.
• Muscle weakness or cramping.
• Difficulty walking or standing.
• Increased susceptibility to fractures.
• Bone deformities in severe cases.

Diagnosis

Diagnosis involves clinical evaluation of symptoms, blood tests to assess vitamin D, calcium, phosphate, and alkaline phosphatase levels, and imaging (e.g., X-rays or bone density scans) to detect bone demineralization. A detailed medication history is critical to identify the causative drug. Exclusion of other causes of osteomalacia is also necessary.

Treatment Options

Treatment focuses on discontinuing or adjusting the offending medication, if possible, and correcting underlying deficiencies. Vitamin D and calcium supplementation are typically initiated to support bone mineralization. Regular monitoring of bone health and medication effects is recommended.

Prognosis and Follow-Up

Prognosis is generally favorable with appropriate treatment, including medication adjustment and supplementation. Follow-up involves regular assessment of bone health, symptom improvement, and monitoring of laboratory values to ensure resolution of mineralization defects.

Complications

• Increased risk of fractures due to bone softening.
• Chronic bone pain or deformities if left untreated.
• Potential for secondary metabolic imbalances (e.g., hypocalcemia).

Lifestyle & Prevention

• Maintain adequate dietary intake of vitamin D and calcium.
• Discuss medication side effects with healthcare providers, especially for long-term drug use.
• Ensure regular sun exposure (with safety considerations) to support vitamin D synthesis.
• Engage in weight-bearing exercises to support bone strength, as advised by a healthcare provider.

When to Seek Professional Help

Seek medical attention if you experience persistent bone pain, unexplained muscle weakness, or difficulty walking, especially if you are taking medications known to affect bone metabolism. Prompt evaluation can prevent complications like fractures.

Tips for Medical Coders

Document the specific drug or class of drugs responsible for the osteomalacia, as this is critical for accurate coding. Ensure the medical record supports the causal relationship between the medication and the condition, including clinical findings and laboratory results. Code M83.5 is appropriate when the osteomalacia is drug-induced and not classified elsewhere.